PL415078A1 - Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków - Google Patents

Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków

Info

Publication number
PL415078A1
PL415078A1 PL415078A PL41507815A PL415078A1 PL 415078 A1 PL415078 A1 PL 415078A1 PL 415078 A PL415078 A PL 415078A PL 41507815 A PL41507815 A PL 41507815A PL 415078 A1 PL415078 A1 PL 415078A1
Authority
PL
Poland
Prior art keywords
diseases
compounds
substituted amino
chitinase inhibitors
mammalian chitinase
Prior art date
Application number
PL415078A
Other languages
English (en)
Inventor
Marzena Mazur
Robert Koralewski
Bartłomiej Borek
Sylwia Olejniczak
Wojciech J. Czestkowski
Michał C. Piotrowicz
Jacek P. Olczak
Adam A. Gołębiowski
Original Assignee
Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością filed Critical Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością
Priority to DK16767368.0T priority Critical patent/DK3344616T3/en
Priority to EP16767368.0A priority patent/EP3344616B1/en
Priority to PE2018000314A priority patent/PE20181048A1/es
Priority to PT16767368T priority patent/PT3344616T/pt
Priority to LTEP16767368.0T priority patent/LT3344616T/lt
Priority to CA2997382A priority patent/CA2997382C/en
Priority to HUE16767368A priority patent/HUE042726T2/hu
Priority to AU2016314345A priority patent/AU2016314345B2/en
Priority to JP2018512339A priority patent/JP6859325B2/ja
Priority to MX2018002659A priority patent/MX368674B/es
Priority to ES16767368T priority patent/ES2717181T3/es
Priority to KR1020187009490A priority patent/KR102699408B1/ko
Priority to SM20190172T priority patent/SMT201900172T1/it
Priority to NZ739711A priority patent/NZ739711B2/en
Priority to HRP20190223TT priority patent/HRP20190223T1/hr
Priority to PL16767368T priority patent/PL3344616T3/pl
Priority to CN201680062288.2A priority patent/CN108290863B/zh
Priority to TR2019/03826T priority patent/TR201903826T4/tr
Priority to PCT/IB2016/055269 priority patent/WO2017037670A1/en
Priority to HK18109046.5A priority patent/HK1249510B/en
Priority to SI201630168T priority patent/SI3344616T1/sl
Priority to MEP-2019-33A priority patent/ME03308B/me
Publication of PL415078A1 publication Critical patent/PL415078A1/pl
Priority to PH12018500286A priority patent/PH12018500286A1/en
Priority to IL257545A priority patent/IL257545B/en
Priority to SA518391033A priority patent/SA518391033B1/ar
Priority to CL2018000564A priority patent/CL2018000564A1/es
Priority to ZA2018/01978A priority patent/ZA201801978B/en
Priority to CONC2018/0003484A priority patent/CO2018003484A2/es
Priority to CY20191100310T priority patent/CY1121432T1/el
Priority to JP2021050972A priority patent/JP2021100966A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)

Abstract

Zgłoszenie ujawnia związki aminotriazolowe podstawione pierścieniem piperydynylowym, który sam jest podstawiony pierścieniem heterocyklicznym. Te związki stanowią inhibitory kwaśnej chitynazy ssaków. Także ujawnione są sposoby stosowania związków do leczenia reakcji astmatycznych powodowanych przez alergeny, jak również ostrych i przewlekłych chorób zapalnych, chorób autoimmunologicznych, chorób zębów, chorób neurologicznych, chorób metabolicznych, choroby wątrób, zespołu Steina i Leventhala, endometriozy, i raka. Zgłoszenie dotyczy także kompozycji farmaceutycznej i farmaceutycznie dopuszczalnego nośnika oraz sposobu hamowania kwaśnej chitynazy ssaków w komórce lub tkance.
PL415078A 2015-09-04 2015-12-04 Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków PL415078A1 (pl)

Priority Applications (30)

Application Number Priority Date Filing Date Title
PCT/IB2016/055269 WO2017037670A1 (en) 2015-09-04 2016-09-02 Substituted amino triazoles useful as human chitinase inhibitors
HRP20190223TT HRP20190223T1 (hr) 2015-09-04 2016-09-02 Supstituirani amino triazoli koji su korisni kao inhibitori ljudske kitinaze
PE2018000314A PE20181048A1 (es) 2015-09-04 2016-09-02 Amino triazoles sustituidos utiles como inhibidores de la quintinasa humana
PT16767368T PT3344616T (pt) 2015-09-04 2016-09-02 Amino triazóis substituídos úteis como inibidores de quitinase humana
LTEP16767368.0T LT3344616T (lt) 2015-09-04 2016-09-02 Pakeisti aminotriazolai, tinkami kaip žmogaus chitinazės inhibitoriai
CA2997382A CA2997382C (en) 2015-09-04 2016-09-02 Substituted amino triazoles useful as human chitinase inhibitors
HUE16767368A HUE042726T2 (hu) 2015-09-04 2016-09-02 Humán kitináz inhibitorként használható szubsztituált aminotriazolok
AU2016314345A AU2016314345B2 (en) 2015-09-04 2016-09-02 Substituted amino triazoles useful as human chitinase inhibitors
JP2018512339A JP6859325B2 (ja) 2015-09-04 2016-09-02 ヒトキチナーゼ阻害剤として有用な置換アミノトリアゾール
MX2018002659A MX368674B (es) 2015-09-04 2016-09-02 Amino triazoles sustituidos útiles como inhibidores de la quitinasa humana.
ES16767368T ES2717181T3 (es) 2015-09-04 2016-09-02 Amino triazoles sustituidos útiles como inhibidores de la quitinasa humana
KR1020187009490A KR102699408B1 (ko) 2015-09-04 2016-09-02 인간 키티나제 저해제로서 유용한 치환된 아미노트라이아졸
SM20190172T SMT201900172T1 (it) 2015-09-04 2016-09-02 Ammino triazoli sostituiti utili come inibitori della chitinasi umana
NZ739711A NZ739711B2 (en) 2016-09-02 Substituted amino triazoles useful as human chitinase inhibitors
PL16767368T PL3344616T3 (pl) 2015-09-04 2016-09-02 Podstawione aminotriazole przydatne jako inhibitory chitynazy ludzkiej
DK16767368.0T DK3344616T3 (en) 2015-09-04 2016-09-02 SUBSTITUTED AMINOTRIAZOLES USED AS HUMAN CHITINASE INHIBITORS
EP16767368.0A EP3344616B1 (en) 2015-09-04 2016-09-02 Substituted amino triazoles useful as human chitinase inhibitors
TR2019/03826T TR201903826T4 (tr) 2015-09-04 2016-09-02 İnsan kitinaz inhibitörleri olarak faydalı ornatılmış amino triazolleri.
CN201680062288.2A CN108290863B (zh) 2015-09-04 2016-09-02 可用作人壳多糖酶抑制剂的经取代的氨基三唑
HK18109046.5A HK1249510B (en) 2015-09-04 2016-09-02 Substituted amino triazoles useful as human chitinase inhibitors
SI201630168T SI3344616T1 (sl) 2015-09-04 2016-09-02 Substituirani amino triazoli, uporabni kot zaviralci človeške hitinaze
MEP-2019-33A ME03308B (me) 2015-09-04 2016-09-02 Supstituisani amino triazoli korisni kao inhibitori humane hitinaze
PH12018500286A PH12018500286A1 (en) 2015-09-04 2018-02-08 Substituted amino triazoles useful as human chitinase inhibitors
IL257545A IL257545B (en) 2015-09-04 2018-02-15 Disubstituted amino triazoles are useful as human chitinase inhibitors
SA518391033A SA518391033B1 (ar) 2015-09-04 2018-02-28 مركبات أمينو ترايازول به استبدال مفيدة باعتبارها مثبطات إنزيم كيتيناز بشري
CL2018000564A CL2018000564A1 (es) 2015-09-04 2018-03-01 Amino triazoles sustituidos útiles como inhibidores de la quitinasa humana.
ZA2018/01978A ZA201801978B (en) 2015-09-04 2018-03-26 Substituted amino triazoles useful as human chitinase inhibitors
CONC2018/0003484A CO2018003484A2 (es) 2015-09-04 2018-03-29 Amino triazoles sustituidos útiles como inhibidores de la quitinasa humana
CY20191100310T CY1121432T1 (el) 2015-09-04 2019-03-15 Υποκατεστημενα αμινοτριαζολια χρησιμα ως αναστολεις ανθρωπινης χιτινασης
JP2021050972A JP2021100966A (ja) 2015-09-04 2021-03-25 ヒトキチナーゼ阻害剤として有用な置換アミノトリアゾール

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562214299P 2015-09-04 2015-09-04

Publications (1)

Publication Number Publication Date
PL415078A1 true PL415078A1 (pl) 2017-03-13

Family

ID=58190067

Family Applications (2)

Application Number Title Priority Date Filing Date
PL415078A PL415078A1 (pl) 2015-09-04 2015-12-04 Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków
PL16767368T PL3344616T3 (pl) 2015-09-04 2016-09-02 Podstawione aminotriazole przydatne jako inhibitory chitynazy ludzkiej

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL16767368T PL3344616T3 (pl) 2015-09-04 2016-09-02 Podstawione aminotriazole przydatne jako inhibitory chitynazy ludzkiej

Country Status (29)

Country Link
US (3) US9944624B2 (pl)
EP (1) EP3344616B1 (pl)
JP (2) JP6859325B2 (pl)
KR (1) KR102699408B1 (pl)
CN (1) CN108290863B (pl)
AU (1) AU2016314345B2 (pl)
CA (1) CA2997382C (pl)
CL (1) CL2018000564A1 (pl)
CO (1) CO2018003484A2 (pl)
CY (1) CY1121432T1 (pl)
DK (1) DK3344616T3 (pl)
ES (1) ES2717181T3 (pl)
HK (1) HK1249510B (pl)
HR (1) HRP20190223T1 (pl)
HU (1) HUE042726T2 (pl)
IL (1) IL257545B (pl)
LT (1) LT3344616T (pl)
ME (1) ME03308B (pl)
MX (1) MX368674B (pl)
PE (1) PE20181048A1 (pl)
PH (1) PH12018500286A1 (pl)
PL (2) PL415078A1 (pl)
PT (1) PT3344616T (pl)
SA (1) SA518391033B1 (pl)
SI (1) SI3344616T1 (pl)
SM (1) SMT201900172T1 (pl)
TR (1) TR201903826T4 (pl)
WO (1) WO2017037670A1 (pl)
ZA (1) ZA201801978B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20161774T1 (hr) 2012-06-13 2017-02-24 F. Hoffmann - La Roche Ag Novi diazaspirocikloalkan i azaspirocikloalkan
BR112015004111A2 (pt) 2012-09-25 2017-07-04 Hoffmann La Roche novos derivados bicíclicos
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
KR20160087900A (ko) 2013-11-26 2016-07-22 에프. 호프만-라 로슈 아게 신규한 옥타하이드로-사이클로부타[1,2-c；3,4-c'']다이피롤-2-일
SI3122750T1 (sl) 2014-03-26 2019-12-31 F. Hoffmann-La Roche Ag Biciklične spojine kot zaviralci proizvodnje avtotaksina (ATX) in lizofosfatidne kisline (LPA)
KR20160128428A (ko) 2014-03-26 2016-11-07 에프. 호프만-라 로슈 아게 오토탁신(atx) 및 리소포스파티드산(lpa) 생성 억제제로서의 축합형 [1,4]다이아제핀 화합물
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
PL415078A1 (pl) 2015-09-04 2017-03-13 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków
JP6886967B2 (ja) 2015-09-04 2021-06-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ フェノキシメチル誘導体
RU2018112230A (ru) 2015-09-24 2019-10-30 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов atx
JP6877413B2 (ja) 2015-09-24 2021-05-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二重ａｔｘ／ｃａ阻害剤としての新規な二環式化合物
AU2016328365B2 (en) 2015-09-24 2020-04-23 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
CN107635995B (zh) 2015-09-24 2022-08-19 豪夫迈·罗氏有限公司 作为atx抑制剂的二环化合物
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
EP3596059B1 (en) 2017-03-16 2024-04-24 F. Hoffmann-La Roche AG Heterocyclic compounds useful as dual atx/ca inhibitors
CN109503449A (zh) * 2018-12-17 2019-03-22 天津药明康德新药开发有限公司 一种3-硝基吖丁啶-1-甲酸叔丁酯的合成方法
AU2020313312A1 (en) * 2019-07-15 2022-03-03 Oncoarendi Therapeutics S.A. Substituted amino triazoles useful as chitinase inhibitors
TWI849432B (zh) * 2019-09-25 2024-07-21 波蘭商摩爾治療股份公司 製造5-(4-((2s,5s)-5-(4-氯芐基)-2-甲基嗎啉基)哌啶-1-基)-1h-1,2,4-三唑-3-胺的方法
EP3854789A1 (en) 2020-01-22 2021-07-28 Cygnet Biosciences B.V. Macrocyclic compounds useful as chitinase inhibitors
CN114057714B (zh) * 2021-11-22 2023-07-14 苏州健雄职业技术学院 杂环基取代的氨基三唑的衍生物及其应用
US12325701B2 (en) * 2022-03-04 2025-06-10 Molecure S.A. YKL-40 inhibitors and their therapeutic
CN116924985B (zh) * 2022-03-29 2026-03-17 山东新时代药业有限公司 一种法舒地尔的制备方法
EP4269400B1 (en) * 2022-04-29 2025-07-09 Molecure SA Ykl-40 inhibitors and their therapeutic applications
CN114957098B (zh) * 2022-06-02 2024-03-29 和鼎（南京）医药技术有限公司 一种制备喷他佐辛中间体的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
SG11201605757SA (en) * 2013-12-20 2016-08-30 Inst Drug Discovery Substituted amino triazoles, and methods using same
US9440953B2 (en) * 2014-12-19 2016-09-13 OncoArendi Therapeutics Sp. z o.o. Substituted amino triazoles useful as acidic mammalian chitinase inhibitors
PL415078A1 (pl) 2015-09-04 2017-03-13 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków

Also Published As

Publication number Publication date
PL3344616T3 (pl) 2019-07-31
ZA201801978B (en) 2019-01-30
AU2016314345A1 (en) 2018-03-01
IL257545A (en) 2018-04-30
US10208020B2 (en) 2019-02-19
KR20180080190A (ko) 2018-07-11
TR201903826T4 (tr) 2019-04-22
KR102699408B1 (ko) 2024-08-28
NZ739711A (en) 2024-05-31
MX368674B (es) 2019-10-10
HRP20190223T1 (hr) 2019-04-05
LT3344616T (lt) 2019-02-25
CN108290863B (zh) 2020-05-05
PH12018500286A1 (en) 2018-08-13
US20190345137A1 (en) 2019-11-14
IL257545B (en) 2020-05-31
US9944624B2 (en) 2018-04-17
SI3344616T1 (sl) 2019-04-30
CA2997382C (en) 2024-01-02
US10538508B2 (en) 2020-01-21
JP2021100966A (ja) 2021-07-08
CY1121432T1 (el) 2020-05-29
EP3344616A1 (en) 2018-07-11
SA518391033B1 (ar) 2022-10-17
CO2018003484A2 (es) 2018-07-10
PE20181048A1 (es) 2018-07-03
AU2016314345B2 (en) 2020-05-07
WO2017037670A1 (en) 2017-03-09
DK3344616T3 (en) 2019-03-18
HUE042726T2 (hu) 2019-07-29
CA2997382A1 (en) 2017-03-09
JP6859325B2 (ja) 2021-04-14
HK1249510B (en) 2019-09-27
US20180258071A1 (en) 2018-09-13
US20170066743A1 (en) 2017-03-09
EP3344616B1 (en) 2019-01-09
ME03308B (me) 2019-10-20
JP2018526399A (ja) 2018-09-13
ES2717181T3 (es) 2019-06-19
CN108290863A (zh) 2018-07-17
MX2018002659A (es) 2018-11-22
PT3344616T (pt) 2019-04-01
CL2018000564A1 (es) 2018-06-29
SMT201900172T1 (it) 2019-05-10

Similar Documents

Publication Publication Date Title
PL415078A1 (pl) Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
EA201790595A1 (ru) Пиримидиноны в качестве ингибиторов фактора xia
EA201491671A1 (ru) Гетероциклильные соединения
EA201491356A1 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
EA201490418A1 (ru) Новые макроциклические соединения в качестве ингибиторов фактора xia
EA201792619A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
PH12013500648A1 (en) Quinazolin-4 (3h) -one derivatives used as pi3 kinase inhibitors
EA201101583A1 (ru) Ингибиторы pi3 киназы или mtor
EA201171415A1 (ru) Ингибиторы белков семейства iap
MD4666B1 (ro) Inhibitori ai Syk
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
EA201591296A1 (ru) Фталазиноны и изохинолиноны в качестве ингибиторов rock
EA201791576A1 (ru) Ингибитор jak
EA201690129A1 (ru) Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента
MD4556B1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
MX390747B (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
EA201790088A1 (ru) Ингибиторы syk
EA201101533A1 (ru) Гетероциклические соединения в качестве ингибиторов mek
NZ711424A (en) Pyridine derivatives as soft rock inhibitors
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201792341A1 (ru) Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap)
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида